Timothy A Springer has bought stock on 16 days since May 2017

Timothy A. Springer is an American biochemist, immunologist, and biophysicist born February 23, 1948, who serves as the Latham Family Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Senior Investigator at Boston Children's Hospital( He is renowned for foundational discoveries in protein allostery, cell adhesion, and immune regulation, particularly his work identifying and characterizing adhesion molecules on lymphocytes and leukocytes( Springer received his PhD from Harvard University and completed postdoctoral training under Nobel laureate César Milstein at Cambridge University(

Springer has been instrumental in translating basic science into clinical therapeutics, with his discoveries leading to six FDA-approved drugs( He founded LeukoSite in 1993, which developed vedolizumab (Entyvio) for ulcerative colitis and Crohn's disease, along with other approved therapeutics before being acquired by Millennium Pharmaceuticals in 1999( Beyond LeukoSite, Springer co-founded Scholar Rock (2012), Morphic Therapeutic (2015), Tectonic Therapeutic (2019), and Seismic Therapeutic (2022), and was a founding investor in Moderna, whose 2018 IPO generated approximately $400 million from his initial $5 million investment( He was honored as a co-recipient of the 2022 Albert Lasker Basic Medical Research Award for his discoveries concerning integrins( and is a member of the National Academy of Sciences( As a member of Cartesian Therapeutics' board of directors since June 2016 and scientific advisor since December 2008( Springer continues to bridge academic research and biotechnology innovation.

Written by Perplexity from public sources.